Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking

Detalhes bibliográficos
Autor(a) principal: TARDAST, Arezo
Data de Publicação: 2015
Outros Autores: SJÖMAN, Reine, LØES, Sigbjørn, ABTAHI, Jahan
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Journal of applied oral science (Online)
Texto Completo: https://www.revistas.usp.br/jaos/article/view/101021
Resumo: Objective There is strong evidence of a link between the use of systemic bisphosphonates (BPs) and osteonecrosis of the jaw, especially in cancer patients. Among risk factors for BRONJ, tooth extraction and immune suppressive drugs seem to have significant role on bone healing. Therefore, the importance of these parameters in development of BRONJ was reviewed in this retrospective study in two maxillofacial surgery units. Material and Methods From 2007 to 2012, 46 patients on bisphosphonate who had developed oral bony lesions participated in this study. The pharmacological exposure, comorbidities, maxillofacial findings, types of treatment and outcome data were collected from clinical and radiological records. Results The most frequently used BP was alendronate (67%). Tooth extraction was reported in 61% of patients with BRONJ. Systemic corticosteroids were prescribed in 35 cases (76%) as an adjuvant for BP. Patients on corticosteroids had a lower probability of bony lesion healing (p
id USP-17_ff78f7d7e8ec4b14fbe1b0befc9639a2
oai_identifier_str oai:revistas.usp.br:article/101021
network_acronym_str USP-17
network_name_str Journal of applied oral science (Online)
repository_id_str
spelling Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking Objective There is strong evidence of a link between the use of systemic bisphosphonates (BPs) and osteonecrosis of the jaw, especially in cancer patients. Among risk factors for BRONJ, tooth extraction and immune suppressive drugs seem to have significant role on bone healing. Therefore, the importance of these parameters in development of BRONJ was reviewed in this retrospective study in two maxillofacial surgery units. Material and Methods From 2007 to 2012, 46 patients on bisphosphonate who had developed oral bony lesions participated in this study. The pharmacological exposure, comorbidities, maxillofacial findings, types of treatment and outcome data were collected from clinical and radiological records. Results The most frequently used BP was alendronate (67%). Tooth extraction was reported in 61% of patients with BRONJ. Systemic corticosteroids were prescribed in 35 cases (76%) as an adjuvant for BP. Patients on corticosteroids had a lower probability of bony lesion healing (pUniversidade de São Paulo. Faculdade de Odontologia de Bauru2015-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/jaos/article/view/10102110.1590/1678-775720140506Journal of Applied Oral Science; Vol. 23 No. 3 (2015); 310-314Journal of Applied Oral Science; Vol. 23 Núm. 3 (2015); 310-314Journal of Applied Oral Science; v. 23 n. 3 (2015); 310-3141678-77651678-7757reponame:Journal of applied oral science (Online)instname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/jaos/article/view/101021/99685Copyright (c) 2015 Journal of Applied Oral Scienceinfo:eu-repo/semantics/openAccessTARDAST, Arezo SJÖMAN, Reine LØES, Sigbjørn ABTAHI, Jahan 2015-07-28T17:30:16Zoai:revistas.usp.br:article/101021Revistahttp://www.scielo.br/jaosPUBhttps://www.revistas.usp.br/jaos/oai||jaos@usp.br1678-77651678-7757opendoar:2015-07-28T17:30:16Journal of applied oral science (Online) - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking
title Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking
spellingShingle Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking
TARDAST, Arezo
title_short Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking
title_full Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking
title_fullStr Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking
title_full_unstemmed Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking
title_sort Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking
author TARDAST, Arezo
author_facet TARDAST, Arezo
SJÖMAN, Reine
LØES, Sigbjørn
ABTAHI, Jahan
author_role author
author2 SJÖMAN, Reine
LØES, Sigbjørn
ABTAHI, Jahan
author2_role author
author
author
dc.contributor.author.fl_str_mv TARDAST, Arezo
SJÖMAN, Reine
LØES, Sigbjørn
ABTAHI, Jahan
description Objective There is strong evidence of a link between the use of systemic bisphosphonates (BPs) and osteonecrosis of the jaw, especially in cancer patients. Among risk factors for BRONJ, tooth extraction and immune suppressive drugs seem to have significant role on bone healing. Therefore, the importance of these parameters in development of BRONJ was reviewed in this retrospective study in two maxillofacial surgery units. Material and Methods From 2007 to 2012, 46 patients on bisphosphonate who had developed oral bony lesions participated in this study. The pharmacological exposure, comorbidities, maxillofacial findings, types of treatment and outcome data were collected from clinical and radiological records. Results The most frequently used BP was alendronate (67%). Tooth extraction was reported in 61% of patients with BRONJ. Systemic corticosteroids were prescribed in 35 cases (76%) as an adjuvant for BP. Patients on corticosteroids had a lower probability of bony lesion healing (p
publishDate 2015
dc.date.none.fl_str_mv 2015-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/jaos/article/view/101021
10.1590/1678-775720140506
url https://www.revistas.usp.br/jaos/article/view/101021
identifier_str_mv 10.1590/1678-775720140506
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/jaos/article/view/101021/99685
dc.rights.driver.fl_str_mv Copyright (c) 2015 Journal of Applied Oral Science
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2015 Journal of Applied Oral Science
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Odontologia de Bauru
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Odontologia de Bauru
dc.source.none.fl_str_mv Journal of Applied Oral Science; Vol. 23 No. 3 (2015); 310-314
Journal of Applied Oral Science; Vol. 23 Núm. 3 (2015); 310-314
Journal of Applied Oral Science; v. 23 n. 3 (2015); 310-314
1678-7765
1678-7757
reponame:Journal of applied oral science (Online)
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Journal of applied oral science (Online)
collection Journal of applied oral science (Online)
repository.name.fl_str_mv Journal of applied oral science (Online) - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||jaos@usp.br
_version_ 1800221678790246400

Registros relacionados